首页 > 最新文献

Veterinary and comparative oncology最新文献

英文 中文
Plasma cell-free DNA in canine lymphoma patients as a novel material for genotyping. 犬淋巴瘤患者血浆中的无细胞 DNA 可作为基因分型的新型材料。
IF 2.1 2区 农林科学 Q1 Veterinary Pub Date : 2024-06-01 Epub Date: 2024-01-29 DOI: 10.1111/vco.12961
Satoshi Kambayashi, Nanae Ono, Tomofumi Tone, Kenji Baba, Masaru Okuda

Canine lymphoma is a disease with high morbidity and poor long-term prognosis, despite a high response rate to chemotherapy. In this study, we focused on liquid biopsy, in which small amounts of substances from body fluids were analysed, to determine whether cell-free DNA (cfDNA) in the plasma can be used as a biomarker for lymphoma in dogs. We found that 23 patients with lymphoma had significantly higher cfDNA concentrations than the 12 healthy dogs (median 2360 ng/mL versus 299 ng/mL, p < .0001). Polymerase chain reaction for antigen receptor rearrangement (PARR) was also employed using cfDNA from the lymphoma group to investigate whether cfDNA could be used for the detection of genetic clonality of lymphomas, as well as the genomic DNA (gDNA) extracted from an original lesion in each case. The correlation of the PARR results between cfDNA and gDNA was observed in 100% of B-cell lymphomas (10/10), 77.8% of T-cell lymphomas (7/9), and 100% of other types of lymphomas (4/4), respectively. These results indicate that plasma cfDNA levels are increasing in canine lymphoma patients, that cfDNA concentration can be a novel diagnostic tool, and that it can be used as a diagnostic tool for PARR.

犬淋巴瘤是一种发病率高、长期预后差的疾病,尽管化疗反应率很高。在这项研究中,我们主要采用液体活检的方法(即对体液中的少量物质进行分析)来确定血浆中的无细胞DNA(cfDNA)是否可用作犬淋巴瘤的生物标志物。我们发现,23 名淋巴瘤患者的 cfDNA 浓度明显高于 12 名健康犬(中位数为 2360 纳克/毫升,而对照组为 299 纳克/毫升,p
{"title":"Plasma cell-free DNA in canine lymphoma patients as a novel material for genotyping.","authors":"Satoshi Kambayashi, Nanae Ono, Tomofumi Tone, Kenji Baba, Masaru Okuda","doi":"10.1111/vco.12961","DOIUrl":"10.1111/vco.12961","url":null,"abstract":"<p><p>Canine lymphoma is a disease with high morbidity and poor long-term prognosis, despite a high response rate to chemotherapy. In this study, we focused on liquid biopsy, in which small amounts of substances from body fluids were analysed, to determine whether cell-free DNA (cfDNA) in the plasma can be used as a biomarker for lymphoma in dogs. We found that 23 patients with lymphoma had significantly higher cfDNA concentrations than the 12 healthy dogs (median 2360 ng/mL versus 299 ng/mL, p < .0001). Polymerase chain reaction for antigen receptor rearrangement (PARR) was also employed using cfDNA from the lymphoma group to investigate whether cfDNA could be used for the detection of genetic clonality of lymphomas, as well as the genomic DNA (gDNA) extracted from an original lesion in each case. The correlation of the PARR results between cfDNA and gDNA was observed in 100% of B-cell lymphomas (10/10), 77.8% of T-cell lymphomas (7/9), and 100% of other types of lymphomas (4/4), respectively. These results indicate that plasma cfDNA levels are increasing in canine lymphoma patients, that cfDNA concentration can be a novel diagnostic tool, and that it can be used as a diagnostic tool for PARR.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo. trastuzumab emtansine 对犬尿路上皮癌细胞在体外和体内的影响。
IF 2.1 2区 农林科学 Q1 Veterinary Pub Date : 2024-06-01 Epub Date: 2024-03-19 DOI: 10.1111/vco.12970
Kosei Sakai, Daiki Kato, Junka Yoshinaka, Yosuke Takahashi, Namiko Ikeda, Susumu Aoki, Takaaki Iguchi, Shingo Ishikawa, Norio Yamagishi, Shunsuke Shimamura, Takayuki Nakagawa

Urothelial carcinoma (UC) is the most common malignancy of the urinary tract in dogs and has aggressive behaviour. Although human epidermal growth factor receptor 2 (HER2) is a known therapeutic target with evidence in canine UC, the efficacy of anti-HER2 antibody drugs remains unknown. This study aimed to investigate the effects of anti-HER2 antibody drugs including trastuzumab and trastuzumab emtansine (T-DM1) on canine UC cell lines in vitro and in vivo. Four canine UC cell lines (Nene, TCCUB, Love, and Sora) were used. In western blotting, HER2 protein expression was observed in all the cell lines. Although both trastuzumab and T-DM1 showed dose-dependent growth inhibitory activity in the cell lines, T-DM1 showed much stronger activity than that of trastuzumab. In flow cytometry analyses with the canine UC cell line (Sora), T-DM1 but not trastuzumab significantly increased the percentages of early and late apoptotic cells in annexin V apoptotic assays and the sub-G1 phase fraction in cell cycle analyses. For the in vivo experiment, the canine UC cells (Sora) were subcutaneously injected into nude mice. Four days after inoculation, trastuzumab, T-DM1, or vehicle was administered intraperitoneally once a week for three times. Tumour volumes were significantly smaller in the T-DM1 group compared to the trastuzumab and vehicle control groups. These findings indicate that T-DM1 exerts a stronger antitumour effect than that of trastuzumab on canine UC cells in vitro and in vivo, possibly by inducing apoptosis due to DM1.

尿路上皮癌(UC)是犬泌尿道最常见的恶性肿瘤,具有侵袭性。虽然人类表皮生长因子受体 2(HER2)是已知的治疗靶点,在犬尿道癌中也有证据,但抗 HER2 抗体药物的疗效仍不清楚。本研究旨在探讨抗HER2抗体药物(包括曲妥珠单抗和曲妥珠单抗埃坦新(T-DM1))在体外和体内对犬UC细胞系的影响。研究使用了四种犬 UC 细胞系(Nene、TCCUB、Love 和 Sora)。在 Western 印迹中,所有细胞系都观察到了 HER2 蛋白的表达。尽管曲妥珠单抗和 T-DM1 对细胞株都表现出剂量依赖性的生长抑制活性,但 T-DM1 比曲妥珠单抗表现出更强的活性。在犬 UC 细胞系(Sora)的流式细胞术分析中,T-DM1 而不是曲妥珠单抗能显著增加附件素 V 凋亡检测中早期和晚期凋亡细胞的百分比,以及细胞周期分析中的亚 G1 期部分。在体内实验中,将犬 UC 细胞(Sora)皮下注射到裸鼠体内。接种四天后,腹腔注射曲妥珠单抗、T-DM1 或药物,每周一次,共注射三次。与曲妥珠单抗和药物对照组相比,T-DM1 组的肿瘤体积明显较小。这些研究结果表明,在体外和体内,T-DM1对犬UC细胞的抗肿瘤作用比曲妥珠单抗更强,这可能是由于DM1诱导了细胞凋亡。
{"title":"Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo.","authors":"Kosei Sakai, Daiki Kato, Junka Yoshinaka, Yosuke Takahashi, Namiko Ikeda, Susumu Aoki, Takaaki Iguchi, Shingo Ishikawa, Norio Yamagishi, Shunsuke Shimamura, Takayuki Nakagawa","doi":"10.1111/vco.12970","DOIUrl":"10.1111/vco.12970","url":null,"abstract":"<p><p>Urothelial carcinoma (UC) is the most common malignancy of the urinary tract in dogs and has aggressive behaviour. Although human epidermal growth factor receptor 2 (HER2) is a known therapeutic target with evidence in canine UC, the efficacy of anti-HER2 antibody drugs remains unknown. This study aimed to investigate the effects of anti-HER2 antibody drugs including trastuzumab and trastuzumab emtansine (T-DM1) on canine UC cell lines in vitro and in vivo. Four canine UC cell lines (Nene, TCCUB, Love, and Sora) were used. In western blotting, HER2 protein expression was observed in all the cell lines. Although both trastuzumab and T-DM1 showed dose-dependent growth inhibitory activity in the cell lines, T-DM1 showed much stronger activity than that of trastuzumab. In flow cytometry analyses with the canine UC cell line (Sora), T-DM1 but not trastuzumab significantly increased the percentages of early and late apoptotic cells in annexin V apoptotic assays and the sub-G1 phase fraction in cell cycle analyses. For the in vivo experiment, the canine UC cells (Sora) were subcutaneously injected into nude mice. Four days after inoculation, trastuzumab, T-DM1, or vehicle was administered intraperitoneally once a week for three times. Tumour volumes were significantly smaller in the T-DM1 group compared to the trastuzumab and vehicle control groups. These findings indicate that T-DM1 exerts a stronger antitumour effect than that of trastuzumab on canine UC cells in vitro and in vivo, possibly by inducing apoptosis due to DM1.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140176759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium iodide symporter immunolabelling as a predictor of clinical iodide uptake in canine thyroid carcinoma: A preliminary study. 碘化钠交感蛋白免疫标记作为犬甲状腺癌临床碘摄取的预测指标:一项初步研究。
IF 2.1 2区 农林科学 Q1 Veterinary Pub Date : 2024-06-01 Epub Date: 2024-03-15 DOI: 10.1111/vco.12971
Katelin V Dark, Owen T Skinner, Dae Young Kim, James J Karnia, Megan A Mickelson, Charles A Maitz

Thyroid follicular tumours may take up iodide via the sodium-iodide symporter. Knowledge of iodide uptake could then allow treatment with I-131 in dogs with high-risk tumours. The objective of this study was to determine the relationship between clinically detectable iodide uptake (as determined by scintigraphy and/or thyroxine concentrations) and sodium iodide symporter immunohistochemical labelling on histologically fixed thyroid tumours. Nineteen dogs were identified who were diagnosed with thyroid carcinoma and underwent surgery from November 2017 to July 2021. All had recorded thyroid hormone concentrations and were hyperthyroid and/or underwent preoperative nuclear imaging using planar scintigraphy (technetium-99m or I-123), or I-124 PET-CT. All dogs subsequently underwent surgery to remove the thyroid mass. Twenty-two tumours were submitted for histopathologic analysis immediately following surgery, which confirmed a diagnosis of thyroid carcinoma for each tumour. Images and/or thyroid hormone concentrations were reviewed for the included cases, and tumours were sorted into an avid/functional group (group 1) and a non-avid/functional group (group 2). The tumour tissues were re-examined histologically using sodium iodide symporter (NIS) immunohistochemistry (IHC). Group 1 contained 15 avid/functional tumours. Twelve of these tumours had membranous NIS IHC labelling. Group 2 contained 7 non-avid tumours. One of these tumours had membranous NIS IHC labelling. This resulted in an overall sensitivity and specificity for identification of avid/functional tumours with membranous NIS of 80.0% and 85.7%, respectively. NIS IHC may predict ion trapping in canine follicular thyroid tumours. Further studies using iodide-based imaging are warranted to better determine the clinical utility of this diagnostic modality.

甲状腺滤泡肿瘤可能通过钠碘交感器吸收碘化物。了解碘摄取情况有助于对患有高危肿瘤的狗进行 I-131 治疗。本研究的目的是确定临床上可检测到的碘摄取量(通过闪烁扫描和/或甲状腺素浓度确定)与组织学固定甲状腺肿瘤上碘化钠交感器免疫组化标记之间的关系。在 2017 年 11 月至 2021 年 7 月期间,共发现了 19 只被诊断为甲状腺癌并接受了手术的狗。所有犬均记录了甲状腺激素浓度,且均为甲状腺功能亢进和/或术前接受了平面闪烁成像(锝-99m或I-123)或I-124 PET-CT核成像检查。所有犬只随后都接受了切除甲状腺肿块的手术。手术后立即对22个肿瘤进行了组织病理学分析,结果确诊每个肿瘤都是甲状腺癌。对纳入病例的图像和/或甲状腺激素浓度进行了复查,并将肿瘤分为有活性/有功能组(第1组)和无活性/无功能组(第2组)。使用碘化钠交感蛋白(NIS)免疫组化(IHC)对肿瘤组织进行组织学复查。第 1 组包含 15 个有活性/功能性肿瘤。其中 12 个肿瘤有膜性 NIS IHC 标记。第 2 组包括 7 个无嗜性肿瘤。其中一个肿瘤有膜性 NIS IHC 标记。因此,鉴定有膜性NIS的阿维德/功能性肿瘤的总体灵敏度和特异度分别为80.0%和85.7%。NIS IHC可预测犬甲状腺滤泡性肿瘤的离子捕获。为了更好地确定这种诊断方式的临床实用性,有必要使用碘化物成像技术开展进一步研究。
{"title":"Sodium iodide symporter immunolabelling as a predictor of clinical iodide uptake in canine thyroid carcinoma: A preliminary study.","authors":"Katelin V Dark, Owen T Skinner, Dae Young Kim, James J Karnia, Megan A Mickelson, Charles A Maitz","doi":"10.1111/vco.12971","DOIUrl":"10.1111/vco.12971","url":null,"abstract":"<p><p>Thyroid follicular tumours may take up iodide via the sodium-iodide symporter. Knowledge of iodide uptake could then allow treatment with I-131 in dogs with high-risk tumours. The objective of this study was to determine the relationship between clinically detectable iodide uptake (as determined by scintigraphy and/or thyroxine concentrations) and sodium iodide symporter immunohistochemical labelling on histologically fixed thyroid tumours. Nineteen dogs were identified who were diagnosed with thyroid carcinoma and underwent surgery from November 2017 to July 2021. All had recorded thyroid hormone concentrations and were hyperthyroid and/or underwent preoperative nuclear imaging using planar scintigraphy (technetium-99m or I-123), or I-124 PET-CT. All dogs subsequently underwent surgery to remove the thyroid mass. Twenty-two tumours were submitted for histopathologic analysis immediately following surgery, which confirmed a diagnosis of thyroid carcinoma for each tumour. Images and/or thyroid hormone concentrations were reviewed for the included cases, and tumours were sorted into an avid/functional group (group 1) and a non-avid/functional group (group 2). The tumour tissues were re-examined histologically using sodium iodide symporter (NIS) immunohistochemistry (IHC). Group 1 contained 15 avid/functional tumours. Twelve of these tumours had membranous NIS IHC labelling. Group 2 contained 7 non-avid tumours. One of these tumours had membranous NIS IHC labelling. This resulted in an overall sensitivity and specificity for identification of avid/functional tumours with membranous NIS of 80.0% and 85.7%, respectively. NIS IHC may predict ion trapping in canine follicular thyroid tumours. Further studies using iodide-based imaging are warranted to better determine the clinical utility of this diagnostic modality.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140132709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of mPGES1 and p16 in feline and human oral squamous cell carcinoma: A comparative oncology approach. 猫科动物和人类口腔鳞状细胞癌中 mPGES1 和 p16 的表达:一种比较肿瘤学方法。
IF 2.1 2区 农林科学 Q1 Veterinary Pub Date : 2024-06-01 Epub Date: 2024-02-20 DOI: 10.1111/vco.12967
Walaa Hamed Shaker Nasry, Kathleen Jones, Juan Carlos Rodriguez-Lecompte, Marvin Tesch, Chelsea K Martin

Comparative cancer studies help us determine if discoveries in one species apply to another. Feline and human oral squamous cell carcinoma (FOSCC and HOSCC) are invasive tumours in which inflammation and abnormal p16 expression are reported. Immunohistochemistry was used to determine the expression of p16 and microsomal prostaglandin E2 synthase 1 (mPGES1) in 42 HOSCC and 45 FOSCC samples with known expression of cyclooxygenase 2 (COX2) and cluster of differentiation 147 (CD147). High p16 expression was more common in HOSCC tumour cells compared to adjacent stroma and oral epithelium (p < .05), with a similar but statistically nonsignificant pattern in FOSCC. Interestingly, high mPGES1 expression in FOSCC was more common in the adjacent epithelium compared to the other compartments (p < .05). In HOSCC, mPGES1 was more similar between compartments but was numerically more common in the tumour compartment (p > .05). There were nominal (p > 0.05) differences in marker expression between high and low mPGES1 expressing tumours in both species, including high p16 observed more commonly in high mPGES1 tumours, and COX-2 positive tumours being more common in low mPGES1 tumours. High CD147 HOSCC tumours were more common in the high mPGES1 HOSCC group (p < .05). In the FOSCC cohort, where there was no statistical difference in CD147 expression between high and low mPGES1 tumours, there were numerically higher CD147 cases in the high mPGES1group. Different expression patterns in FOSCC and HOSCC could be related to different risk factors. For example, p16 is a marker of papillomavirus-driven HOSCC, but a causal relationship between papillomaviruses and FOSCC has yet to be definitively demonstrated. The significance of high P16 expression in the absence of papillomavirus infection deserves further study, and the relative contributions of COX2 and mPGES1 to tumour inflammation and progression should be explored. The findings reveal potential similarities in FOSCC and HOSCC biology, while also demonstrating differences that may relate to risk factors and pathogenesis that are unique to each species.

癌症比较研究有助于我们确定在一个物种中的发现是否适用于另一个物种。猫科动物和人类口腔鳞状细胞癌(FOSCC 和 HOSCC)都是侵袭性肿瘤,其中有炎症和 p16 表达异常的报道。研究人员采用免疫组化方法测定了 42 个 HOSCC 和 45 个 FOSCC 样本中 p16 和微粒体前列腺素 E2 合成酶 1(mPGES1)的表达,这些样本中已知有环氧合酶 2(COX2)和分化簇 147(CD147)的表达。与邻近的基质和口腔上皮细胞相比,p16 高表达在 HOSCC 肿瘤细胞中更为常见(p .05)。在这两种肿瘤中,mPGES1 表达高的肿瘤和表达低的肿瘤在标记物表达上存在名义上的差异(p > 0.05),包括高 p16 表达在高 mPGES1 肿瘤中更常见,COX-2 阳性肿瘤在低 mPGES1 肿瘤中更常见。高 CD147 HOSCC 肿瘤在高 mPGES1 HOSCC 组中更为常见(p
{"title":"Expression of mPGES1 and p16 in feline and human oral squamous cell carcinoma: A comparative oncology approach.","authors":"Walaa Hamed Shaker Nasry, Kathleen Jones, Juan Carlos Rodriguez-Lecompte, Marvin Tesch, Chelsea K Martin","doi":"10.1111/vco.12967","DOIUrl":"10.1111/vco.12967","url":null,"abstract":"<p><p>Comparative cancer studies help us determine if discoveries in one species apply to another. Feline and human oral squamous cell carcinoma (FOSCC and HOSCC) are invasive tumours in which inflammation and abnormal p16 expression are reported. Immunohistochemistry was used to determine the expression of p16 and microsomal prostaglandin E2 synthase 1 (mPGES1) in 42 HOSCC and 45 FOSCC samples with known expression of cyclooxygenase 2 (COX2) and cluster of differentiation 147 (CD147). High p16 expression was more common in HOSCC tumour cells compared to adjacent stroma and oral epithelium (p < .05), with a similar but statistically nonsignificant pattern in FOSCC. Interestingly, high mPGES1 expression in FOSCC was more common in the adjacent epithelium compared to the other compartments (p < .05). In HOSCC, mPGES1 was more similar between compartments but was numerically more common in the tumour compartment (p > .05). There were nominal (p > 0.05) differences in marker expression between high and low mPGES1 expressing tumours in both species, including high p16 observed more commonly in high mPGES1 tumours, and COX-2 positive tumours being more common in low mPGES1 tumours. High CD147 HOSCC tumours were more common in the high mPGES1 HOSCC group (p < .05). In the FOSCC cohort, where there was no statistical difference in CD147 expression between high and low mPGES1 tumours, there were numerically higher CD147 cases in the high mPGES1group. Different expression patterns in FOSCC and HOSCC could be related to different risk factors. For example, p16 is a marker of papillomavirus-driven HOSCC, but a causal relationship between papillomaviruses and FOSCC has yet to be definitively demonstrated. The significance of high P16 expression in the absence of papillomavirus infection deserves further study, and the relative contributions of COX2 and mPGES1 to tumour inflammation and progression should be explored. The findings reveal potential similarities in FOSCC and HOSCC biology, while also demonstrating differences that may relate to risk factors and pathogenesis that are unique to each species.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139913583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urinary and household chemical exposures in pet dogs with urothelial cell carcinoma. 患尿道细胞癌的宠物狗接触尿液和家用化学品的情况。
IF 2.1 2区 农林科学 Q1 Veterinary Pub Date : 2024-06-01 Epub Date: 2024-02-22 DOI: 10.1111/vco.12968
Samantha L Braman, Hannah Peterson, Amy Elbe, Erin Mani, Camille Danielson, Christa Dahman, Julia D Labadie, Lauren A Trepanier

Urothelial cell carcinoma (UCC) has been linked to environmental chemical exposures in people, but these risk factors are not well understood in dogs with UCC. We hypothesised that household chemical exposures contribute to the risk of UCC in pet dogs. This prospective cross-sectional case-control study included 37 dogs with UCC and 37 unaffected breed-, sex-, and age-matched controls. Dog owners completed an environmental questionnaire and household samples were collected and analysed for arsenic (in tap water and room dust) and acrolein (in room air). Urine samples from UCC dogs, control dogs, and consenting owners were analysed for inorganic arsenic species, the acrolein metabolite 3-HPMA, and the phenoxy herbicide 2,4-D. Public data on chlorination byproducts (total trihalomethanes) in municipal drinking water were also compared between case and control households. Dogs with UCC were more likely to swim in a pool (15.2%) compared with control dogs (0%) (OR 1.69, 95% CI = 1.69-∞; p = .02). Dogs with UCC also had more than 4-fold higher reported municipal water concentrations of chlorination byproducts (median 28.0 ppb) compared with controls (median 6.9 ppb; p < .0001). Dust arsenic concentrations were unexpectedly lower in case households (median 0.277 ng/cm2) compared with control households (median 0.401 ng/cm2; p = .0002). Other outcomes were not significantly different between groups. These data suggest that dog owners, especially those of breeds known to be at higher risk for UCC, consider limiting access to swimming pools and installing water filtration units that remove total trihalomethanes.

人的尿道上皮细胞癌(UCC)与环境中的化学物质接触有关,但对于患有 UCC 的宠物狗来说,这些风险因素还不是很清楚。我们假设家庭化学品暴露会增加宠物狗患 UCC 的风险。这项前瞻性横断面病例对照研究包括 37 只患有 UCC 的狗和 37 只在品种、性别和年龄上与之匹配的未受影响的对照组。狗的主人填写了一份环境调查问卷,并收集了家庭样本,对其中的砷(自来水和室内灰尘中的砷)和丙烯醛(室内空气中的)进行了分析。对 UCC 狗、对照组狗和同意的狗主人的尿液样本进行了无机砷、丙烯醛代谢物 3-HPMA 和苯氧基除草剂 2,4-D 的分析。此外,还比较了病例家庭和对照家庭的市政饮用水中氯化副产物(总三卤甲烷)的公开数据。与对照组(0%)相比,患有 UCC 的狗(15.2%)更有可能在游泳池游泳(OR 1.69,95% CI = 1.69-∞;P = .02)。与对照组(中位数为 6.9 ppb; p 2 )相比,患有 UCC 的狗报告的市政水中氯化副产物浓度(中位数为 28.0 ppb)比对照组(中位数为 0.401 ng/cm2; p = .0002)高出 4 倍多。其他结果在组间无明显差异。这些数据表明,狗的主人,尤其是那些已知患 UCC 风险较高的狗种的主人,应考虑限制狗进入游泳池,并安装可去除总三卤甲烷的水过滤装置。
{"title":"Urinary and household chemical exposures in pet dogs with urothelial cell carcinoma.","authors":"Samantha L Braman, Hannah Peterson, Amy Elbe, Erin Mani, Camille Danielson, Christa Dahman, Julia D Labadie, Lauren A Trepanier","doi":"10.1111/vco.12968","DOIUrl":"10.1111/vco.12968","url":null,"abstract":"<p><p>Urothelial cell carcinoma (UCC) has been linked to environmental chemical exposures in people, but these risk factors are not well understood in dogs with UCC. We hypothesised that household chemical exposures contribute to the risk of UCC in pet dogs. This prospective cross-sectional case-control study included 37 dogs with UCC and 37 unaffected breed-, sex-, and age-matched controls. Dog owners completed an environmental questionnaire and household samples were collected and analysed for arsenic (in tap water and room dust) and acrolein (in room air). Urine samples from UCC dogs, control dogs, and consenting owners were analysed for inorganic arsenic species, the acrolein metabolite 3-HPMA, and the phenoxy herbicide 2,4-D. Public data on chlorination byproducts (total trihalomethanes) in municipal drinking water were also compared between case and control households. Dogs with UCC were more likely to swim in a pool (15.2%) compared with control dogs (0%) (OR 1.69, 95% CI = 1.69-∞; p = .02). Dogs with UCC also had more than 4-fold higher reported municipal water concentrations of chlorination byproducts (median 28.0 ppb) compared with controls (median 6.9 ppb; p < .0001). Dust arsenic concentrations were unexpectedly lower in case households (median 0.277 ng/cm<sup>2</sup>) compared with control households (median 0.401 ng/cm<sup>2</sup>; p = .0002). Other outcomes were not significantly different between groups. These data suggest that dog owners, especially those of breeds known to be at higher risk for UCC, consider limiting access to swimming pools and installing water filtration units that remove total trihalomethanes.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feline high-grade and large granular lymphocyte alimentary lymphomas treated with COP- or CHOP-based chemotherapy: A multi-centric retrospective study of 57 cases. 以 COP 或 CHOP 为基础的化疗治疗猫高级别和大颗粒淋巴细胞消化道淋巴瘤:对 57 例病例的多中心回顾性研究。
IF 2.1 2区 农林科学 Q1 Veterinary Pub Date : 2024-06-01 Epub Date: 2024-02-14 DOI: 10.1111/vco.12965
Grégoire Bernardo Marques, Frédérique Ponce, Claire Beaudu-Lange, Jérémy Béguin, Laurie Boissy, Thomas Chavalle, Pauline Denoeux, Nicolas Diop, Livia Ferro, Franck Floch, Mathilde Lajoinie, David Sayag, Laura E Barrett, Gabriel Chamel

Specific data regarding outcome of cats with high-grade and large granular lymphocyte alimentary lymphoma (HGAL and LGL, respectively) treated with multi-agent chemotherapy are scarce. The aims of this multi-centric, retrospective study were to describe the outcome of cats with HGAL and LGL treated with COP- or CHOP-based chemotherapy and to identify potential prognostic factors. Cats with a cytological or histological diagnosis of HGAL or LGL lymphoma treated with COP- or CHOP-based protocol as first-line chemotherapy were included. Data regarding diagnosis, staging, treatment and follow-up were collected. Fifty-seven cats treated with CHOP (n = 37) or COP (n = 20) protocols were included. Complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) were observed in 20%, 22%, 36% and 22% of cats, respectively, for an overall response rate of 42%. Median progression-free interval (PFI) was 148 days and overall median survival time (OST) was 131 days. Cats achieving CR, PR or SD showed significantly longer PFI (p < .01) and OST (p < .015) compared with cats with PD. Other positive prognostic factors in multi-variate analysis were rescue treatment (p < .001) and absence of lymph node involvement (p < .03). Negative prognostic factors were diffuse infiltration of the gastrointestinal tract (p = .035) and infiltration of a non-haematopoietic organ (p < .01).

有关猫高级别和大颗粒淋巴细胞消化道淋巴瘤(分别为HGAL和LGL)多药化疗结果的具体数据很少。这项多中心回顾性研究的目的是描述以 COP 或 CHOP 为基础的化疗对 HGAL 和 LGL 猫的疗效,并确定潜在的预后因素。研究纳入了细胞学或组织学诊断为HGAL或LGL淋巴瘤并接受COP或CHOP方案作为一线化疗的猫。收集了有关诊断、分期、治疗和随访的数据。纳入了57只接受CHOP(37只)或COP(20只)方案治疗的猫。分别有20%、22%、36%和22%的猫出现完全应答(CR)、部分应答(PR)、疾病稳定(SD)和疾病进展(PD),总应答率为42%。无进展间隔中位数(PFI)为 148 天,总生存时间中位数(OST)为 131 天。获得 CR、PR 或 SD 的猫的无进展间隔时间明显更长(P
{"title":"Feline high-grade and large granular lymphocyte alimentary lymphomas treated with COP- or CHOP-based chemotherapy: A multi-centric retrospective study of 57 cases.","authors":"Grégoire Bernardo Marques, Frédérique Ponce, Claire Beaudu-Lange, Jérémy Béguin, Laurie Boissy, Thomas Chavalle, Pauline Denoeux, Nicolas Diop, Livia Ferro, Franck Floch, Mathilde Lajoinie, David Sayag, Laura E Barrett, Gabriel Chamel","doi":"10.1111/vco.12965","DOIUrl":"10.1111/vco.12965","url":null,"abstract":"<p><p>Specific data regarding outcome of cats with high-grade and large granular lymphocyte alimentary lymphoma (HGAL and LGL, respectively) treated with multi-agent chemotherapy are scarce. The aims of this multi-centric, retrospective study were to describe the outcome of cats with HGAL and LGL treated with COP- or CHOP-based chemotherapy and to identify potential prognostic factors. Cats with a cytological or histological diagnosis of HGAL or LGL lymphoma treated with COP- or CHOP-based protocol as first-line chemotherapy were included. Data regarding diagnosis, staging, treatment and follow-up were collected. Fifty-seven cats treated with CHOP (n = 37) or COP (n = 20) protocols were included. Complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) were observed in 20%, 22%, 36% and 22% of cats, respectively, for an overall response rate of 42%. Median progression-free interval (PFI) was 148 days and overall median survival time (OST) was 131 days. Cats achieving CR, PR or SD showed significantly longer PFI (p < .01) and OST (p < .015) compared with cats with PD. Other positive prognostic factors in multi-variate analysis were rescue treatment (p < .001) and absence of lymph node involvement (p < .03). Negative prognostic factors were diffuse infiltration of the gastrointestinal tract (p = .035) and infiltration of a non-haematopoietic organ (p < .01).</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139736234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Magnetic resonance and computed tomographic imaging characteristics and potential molecular mechanisms of feline meningioma associated calvarial hyperostosis. 猫脑膜瘤伴骨钙化症的磁共振和计算机断层扫描成像特征及潜在分子机制。
IF 2.1 2区 农林科学 Q1 Veterinary Pub Date : 2024-06-01 Epub Date: 2024-02-08 DOI: 10.1111/vco.12964
Michael R Edwards, Josefa K Garcia Mora, Kayla M Fowler, Christina Vezza, John L Robertson, Gregory B Daniel, Richard L Shinn, Rell L Parker, Stephen R Werre, John H Rossmeisl

Meningiomas are the most common feline primary brain tumours, and calvarial hyperostosis (CH) is frequently documented in association with this neoplastic entity. The clinical significance of and mechanisms driving the formation of CH in cats with meningiomas are poorly understood, although tumour invasion into the skull and tumour production of cytokines and enzymes have been implicated as causes of CH in humans. This retrospective study investigated relationships between signalment, MRI or CT imaging features, histopathologic tumour characteristics, alkaline phosphatase (ALP) isoenzyme concentrations, tumour expression of matrix metalloproteinases (MMP)-2, MMP-9, and interleukin-6 (IL-6), and progression free survival times (PFS) following surgical treatment in 27 cats with meningiomas with (n = 15) or without (n = 12) evidence of CH. No significant differences in breed, age, sex, body weight, tumour grade, tumour volume, peritumoral edema burden, ALP isoenzyme concentrations, tumour Ki-67 labelling indices or MMP-2 or MMP-9 expression and activity, or PFS were noted between cats with or without CH. There was a trend towards higher serum (p = .06) and intratumoral (p = .07) concentrations of IL-6 in cats with CH, but these comparisons were not statistically significant. Histologic evidence of tumour invasion into bone was observed in 5/12 (42%) with CH and in no (0/6) cats without CH, although this was not statistically significant (p = .07). Tumour invasion into bone and tumour production of IL-6 may contribute to the formation of meningioma associated CH in cats, although larger studies are required to further substantiate these findings and determine their clinical relevance.

脑膜瘤是猫科动物最常见的原发性脑肿瘤,颅骨骨质增生(CH)经常与这种肿瘤实体相关联。尽管肿瘤侵入颅骨以及肿瘤产生细胞因子和酶被认为是导致人类颅骨骨质增生的原因,但人们对猫脑膜瘤患者颅骨骨质增生的临床意义和形成机制知之甚少。这项回顾性研究调查了 27 只有(15 只)或无(12 只)CH 证据的脑膜瘤猫的信号、MRI 或 CT 成像特征、肿瘤组织病理学特征、碱性磷酸酶 (ALP) 同工酶浓度、基质金属蛋白酶 (MMP)-2、MMP-9 和白细胞介素-6 (IL-6) 的肿瘤表达以及手术治疗后无进展生存时间 (PFS) 之间的关系。有或没有CH的猫在品种、年龄、性别、体重、肿瘤等级、肿瘤体积、瘤周水肿负荷、ALP同工酶浓度、肿瘤Ki-67标记指数或MMP-2或MMP-9表达和活性以及PFS方面均无明显差异。患有 CH 的猫血清(p = .06)和瘤内(p = .07)IL-6 浓度有升高的趋势,但这些比较没有统计学意义。在 5/12 只(42%)患有 CH 的猫和 0/6 只(0/6)未患有 CH 的猫中观察到肿瘤侵入骨骼的组织学证据,但无统计学意义(p = .07)。肿瘤侵入骨骼和肿瘤产生 IL-6 可能会导致猫脑膜瘤相关 CH 的形成,但还需要更大规模的研究来进一步证实这些发现并确定其临床相关性。
{"title":"Magnetic resonance and computed tomographic imaging characteristics and potential molecular mechanisms of feline meningioma associated calvarial hyperostosis.","authors":"Michael R Edwards, Josefa K Garcia Mora, Kayla M Fowler, Christina Vezza, John L Robertson, Gregory B Daniel, Richard L Shinn, Rell L Parker, Stephen R Werre, John H Rossmeisl","doi":"10.1111/vco.12964","DOIUrl":"10.1111/vco.12964","url":null,"abstract":"<p><p>Meningiomas are the most common feline primary brain tumours, and calvarial hyperostosis (CH) is frequently documented in association with this neoplastic entity. The clinical significance of and mechanisms driving the formation of CH in cats with meningiomas are poorly understood, although tumour invasion into the skull and tumour production of cytokines and enzymes have been implicated as causes of CH in humans. This retrospective study investigated relationships between signalment, MRI or CT imaging features, histopathologic tumour characteristics, alkaline phosphatase (ALP) isoenzyme concentrations, tumour expression of matrix metalloproteinases (MMP)-2, MMP-9, and interleukin-6 (IL-6), and progression free survival times (PFS) following surgical treatment in 27 cats with meningiomas with (n = 15) or without (n = 12) evidence of CH. No significant differences in breed, age, sex, body weight, tumour grade, tumour volume, peritumoral edema burden, ALP isoenzyme concentrations, tumour Ki-67 labelling indices or MMP-2 or MMP-9 expression and activity, or PFS were noted between cats with or without CH. There was a trend towards higher serum (p = .06) and intratumoral (p = .07) concentrations of IL-6 in cats with CH, but these comparisons were not statistically significant. Histologic evidence of tumour invasion into bone was observed in 5/12 (42%) with CH and in no (0/6) cats without CH, although this was not statistically significant (p = .07). Tumour invasion into bone and tumour production of IL-6 may contribute to the formation of meningioma associated CH in cats, although larger studies are required to further substantiate these findings and determine their clinical relevance.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation toxicity grading after chemoradiotherapy of canine urinary tract carcinomas: Comparing VRTOG to VRTOG_v2.0. 犬尿路癌化放疗后的放射毒性分级:VRTOG 与 VRTOG_v2.0 的比较。
IF 2.1 2区 农林科学 Q1 Veterinary Pub Date : 2024-06-01 Epub Date: 2024-03-27 DOI: 10.1111/vco.12973
Carlotta Ahrens, Laura Beatrice, Valeria Meier, Carla Rohrer Bley

Radiation toxicities may be underestimated after treatment of transitional cell carcinoma in dogs' lower urinary tract. Assessing acute and late toxicities and differentiating them from progressive disease (PD) impacts further therapeutic approach. We retrospectively assessed dogs treated with definitive-intent chemoradiotherapy (12 × 3.8 Gy, various first-line chemotherapeutics). Local tumour control, radiation toxicities and survival were evaluated. We classified radiation toxicities according to the previously published radiation toxicity scheme "VRTOG" as well as the updated version, "VRTOG_v2.0". Fourteen dogs with transitional cell carcinoma of bladder ± urethra (n = 8), +prostate (n = 3) or solely urethra (n = 3), were included. Median follow-up was 298 days (range 185-1798 days), median overall survival 305 days (95%CI = 209;402) and 28.6% deaths were tumour-progression-related. Acute radiation toxicity was mild and self-limiting with both classification systems: In VRTOG, 5 dogs showed grade 1, and 1 dog grade 2 toxicity. In VRTOG_v2.0, 2 dogs showed grade 1, 3 dogs grade 2, and 3 dogs grade 3 toxicity. Late toxicity was noted in 14.2% of dogs (2/14) with the VRTOG, both with grade 3 toxicity. With VRTOG_v2.0, a larger proportion of 42.9% of dogs (6/14) showed late toxicities: Four dogs grade 3 (persistent incontinence), 2 dogs grade 5 (urethral obstructions without PD resulting in euthanasia). At time of death, 5 dogs underwent further workup and only 3 were confirmed to have PD. With the updated VRTOG_v2.0 classification system, more dogs with probable late toxicity are registered, but it is ultimately difficult to distinguish these from disease progression as restaging remains to be the most robust determinant.

狗下尿路过渡细胞癌治疗后的放射毒性可能被低估。评估急性和晚期毒性并将其与进展性疾病(PD)区分开来会影响进一步的治疗方法。我们回顾性地评估了接受确定性意向化放疗(12 × 3.8 Gy,各种一线化疗药物)治疗的狗。对局部肿瘤控制、放疗毒性和存活率进行了评估。我们根据之前发布的放射毒性计划 "VRTOG "和更新版 "VRTOG_v2.0 "对放射毒性进行了分类。共纳入了 14 只患有膀胱(含尿道)、前列腺(含尿道)或单纯尿道(含尿道)过渡细胞癌的狗。中位随访时间为 298 天(185-1798 天不等),中位总生存期为 305 天(95%CI = 209;402),28.6% 的死亡与肿瘤进展有关。两种分类系统的急性放射毒性都很轻微,且具有自限性:在 VRTOG 中,5 只狗出现了 1 级毒性,1 只狗出现了 2 级毒性。在 VRTOG_v2.0 中,2 只狗出现 1 级毒性,3 只狗出现 2 级毒性,3 只狗出现 3 级毒性。使用 VRTOG 时,14.2% 的狗(2/14)出现了晚期毒性,均为 3 级毒性。使用 VRTOG_v2.0,42.9% 的狗(6/14)出现了较高比例的晚期毒性:4 只狗出现了 3 级毒性(持续性尿失禁),2 只狗出现了 5 级毒性(尿道梗阻,但没有导致安乐死)。死亡时,5 只狗接受了进一步检查,只有 3 只狗被证实患有 PD。随着VRTOG_v2.0分类系统的更新,更多可能有晚期毒性的狗被登记在册,但最终很难将这些狗与疾病进展区分开来,因为重新分期仍然是最有力的决定因素。
{"title":"Radiation toxicity grading after chemoradiotherapy of canine urinary tract carcinomas: Comparing VRTOG to VRTOG_v2.0.","authors":"Carlotta Ahrens, Laura Beatrice, Valeria Meier, Carla Rohrer Bley","doi":"10.1111/vco.12973","DOIUrl":"10.1111/vco.12973","url":null,"abstract":"<p><p>Radiation toxicities may be underestimated after treatment of transitional cell carcinoma in dogs' lower urinary tract. Assessing acute and late toxicities and differentiating them from progressive disease (PD) impacts further therapeutic approach. We retrospectively assessed dogs treated with definitive-intent chemoradiotherapy (12 × 3.8 Gy, various first-line chemotherapeutics). Local tumour control, radiation toxicities and survival were evaluated. We classified radiation toxicities according to the previously published radiation toxicity scheme \"VRTOG\" as well as the updated version, \"VRTOG_v2.0\". Fourteen dogs with transitional cell carcinoma of bladder ± urethra (n = 8), +prostate (n = 3) or solely urethra (n = 3), were included. Median follow-up was 298 days (range 185-1798 days), median overall survival 305 days (95%CI = 209;402) and 28.6% deaths were tumour-progression-related. Acute radiation toxicity was mild and self-limiting with both classification systems: In VRTOG, 5 dogs showed grade 1, and 1 dog grade 2 toxicity. In VRTOG_v2.0, 2 dogs showed grade 1, 3 dogs grade 2, and 3 dogs grade 3 toxicity. Late toxicity was noted in 14.2% of dogs (2/14) with the VRTOG, both with grade 3 toxicity. With VRTOG_v2.0, a larger proportion of 42.9% of dogs (6/14) showed late toxicities: Four dogs grade 3 (persistent incontinence), 2 dogs grade 5 (urethral obstructions without PD resulting in euthanasia). At time of death, 5 dogs underwent further workup and only 3 were confirmed to have PD. With the updated VRTOG_v2.0 classification system, more dogs with probable late toxicity are registered, but it is ultimately difficult to distinguish these from disease progression as restaging remains to be the most robust determinant.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A retrospective Italian Society of Veterinary Oncology (SIONCOV) study of 56 cats with appendicular osteosarcoma. 意大利兽医肿瘤学会(SIONCOV)对 56 只患有阑尾骨肉瘤的猫进行了回顾性研究。
IF 2.1 2区 农林科学 Q1 Veterinary Pub Date : 2024-06-01 Epub Date: 2024-02-07 DOI: 10.1111/vco.12966
Laura Marconato, Maurizio Annoni, Federico Massari, Stefano Zanardi, Damiano Stefanello, Roberta Ferrari, Federica Rossi, Vincenzo Montinaro, Emanuela Morello, Carmit Chalfon, Marco De Lorenzi, Daniela Murgia, Dario Drudi, Gabriele Truncellito, Emanuele Cabibbo, Silvia Sabattini

Osteosarcoma is the most common malignant primary bone cancer, but it is infrequently reported in cats. Feline appendicular osteosarcoma typically exhibits good prognosis when treated with surgery alone. A retrospective multi-institutional study was conducted to identify possible prognostic factors. Cats diagnosed with appendicular osteosarcoma were included if initial staging and follow-up information were available. Data including signalment, tumour characteristics, treatment modalities, and survival outcomes were collected and analysed. Fifty-six cats were included; the femur was the most frequently affected bone. Eight cats had distant metastasis at admission and an additional 9 developed metastatic disease during follow-up, resulting in an overall metastatic rate of 30%. Forty-nine (87.5%) cats underwent surgery, and 4 also received adjuvant chemotherapy. Among operated cats, median time to local progression (TTLP), time to distant progression and tumour-specific survival (TSS) were not reached. One- and 2-year survival rates were 66% and 55%, respectively. Seven (12.5%) cats received no treatment; 1- and 2-year survival rates were 25% and 0%, respectively. Operated cats had significantly longer TTLP (P < .001) and TSS (P = .001) compared with non-operated cats. Among operated cats, young age negatively impacted local tumour progression, while the presence of distant metastasis at diagnosis was associated with a higher risk of tumour-related death. This study reaffirms the good prognosis for cats with appendicular osteosarcoma undergoing surgery, but sheds light on some additional factors to consider. Accurate initial staging is recommended, as the metastatic rate may exceed many previous estimations. Surgery substantially extends survival time, whereas the role of chemotherapy remains uncertain.

骨肉瘤是最常见的恶性原发性骨癌,但在猫科动物中却鲜有报道。猫的阑尾骨肉瘤在单纯手术治疗时通常预后良好。我们进行了一项多机构回顾性研究,以确定可能的预后因素。如果有初步分期和随访信息,则纳入诊断为阑尾骨肉瘤的猫。研究收集并分析了包括信号、肿瘤特征、治疗方式和生存结果在内的数据。研究共纳入了 56 只猫;股骨是最常受影响的骨骼。入院时有 8 只猫出现远处转移,另有 9 只在随访期间出现转移,总转移率为 30%。49只(87.5%)猫接受了手术,4只还接受了辅助化疗。在接受手术的猫咪中,局部进展时间(TTLP)、远处进展时间和肿瘤特异性生存率(TSS)均未达到中位数。一年和两年生存率分别为 66% 和 55%。7只猫(12.5%)未接受治疗;1年和2年存活率分别为25%和0%。手术猫的 TTLP 明显更长(P
{"title":"A retrospective Italian Society of Veterinary Oncology (SIONCOV) study of 56 cats with appendicular osteosarcoma.","authors":"Laura Marconato, Maurizio Annoni, Federico Massari, Stefano Zanardi, Damiano Stefanello, Roberta Ferrari, Federica Rossi, Vincenzo Montinaro, Emanuela Morello, Carmit Chalfon, Marco De Lorenzi, Daniela Murgia, Dario Drudi, Gabriele Truncellito, Emanuele Cabibbo, Silvia Sabattini","doi":"10.1111/vco.12966","DOIUrl":"10.1111/vco.12966","url":null,"abstract":"<p><p>Osteosarcoma is the most common malignant primary bone cancer, but it is infrequently reported in cats. Feline appendicular osteosarcoma typically exhibits good prognosis when treated with surgery alone. A retrospective multi-institutional study was conducted to identify possible prognostic factors. Cats diagnosed with appendicular osteosarcoma were included if initial staging and follow-up information were available. Data including signalment, tumour characteristics, treatment modalities, and survival outcomes were collected and analysed. Fifty-six cats were included; the femur was the most frequently affected bone. Eight cats had distant metastasis at admission and an additional 9 developed metastatic disease during follow-up, resulting in an overall metastatic rate of 30%. Forty-nine (87.5%) cats underwent surgery, and 4 also received adjuvant chemotherapy. Among operated cats, median time to local progression (TTLP), time to distant progression and tumour-specific survival (TSS) were not reached. One- and 2-year survival rates were 66% and 55%, respectively. Seven (12.5%) cats received no treatment; 1- and 2-year survival rates were 25% and 0%, respectively. Operated cats had significantly longer TTLP (P < .001) and TSS (P = .001) compared with non-operated cats. Among operated cats, young age negatively impacted local tumour progression, while the presence of distant metastasis at diagnosis was associated with a higher risk of tumour-related death. This study reaffirms the good prognosis for cats with appendicular osteosarcoma undergoing surgery, but sheds light on some additional factors to consider. Accurate initial staging is recommended, as the metastatic rate may exceed many previous estimations. Surgery substantially extends survival time, whereas the role of chemotherapy remains uncertain.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139703531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of companion animal models in radiopharmaceutical development and translation. 伴侣动物模型在放射性药物开发和转化中的作用。
IF 2.1 2区 农林科学 Q1 Veterinary Pub Date : 2024-06-01 Epub Date: 2024-03-05 DOI: 10.1111/vco.12969
Charles A Maitz, Jeffrey N Bryan

Advancements in molecular imaging and drug targeting have created a renaissance in the development of radiopharmaceuticals for therapy and theranostics. While some radiopharmaceuticals, such as Na[131I]I, have been used clinically for decades, new agents are being approved using small-molecules, peptides, and antibodies for targeting. As these agents are being developed, the need to understand dosimetry and biologic effects of the systemically delivered radiotherapy becomes more important, particularly as highly potent radiopharmaceuticals using targeted alpha therapy become clinically utilized. As the processes being targeted become more complex, and the radiobiology of different particulate radiation becomes more diverse, models that better recapitulate human cancer and geometry are necessary. Companion animals develop many of the same types of cancer, carrying many of the same genetic drivers as those seen in people, and the scale and geometry of tumours in dogs more closely mimics those in humans than murine tumour models. Key translational challenges in oncology, such as alterations in tumour microenvironment, hypoxia, heterogeneity, and geometry are addressed by companion animal models. This review paper will provide background on radiopharmaceutical targeting techniques, review the use of radiopharmaceuticals in companion animal oncology, and explore the translational value of treating these patients in terms of dosimetry, treatment outcomes, and normal tissue complication rates.

分子成像和药物靶向技术的进步推动了用于治疗和疗法的放射性药物的发展。虽然一些放射性药物(如 Na[131 I]I)已在临床上使用了几十年,但使用小分子、肽和抗体进行靶向的新药物正在获得批准。随着这些药物的不断开发,了解全身放疗的剂量学和生物效应变得越来越重要,尤其是当使用α靶向治疗的高能放射性药物在临床上得到应用时。随着靶向过程变得越来越复杂,不同微粒辐射的放射生物学也变得越来越多样化,因此有必要建立能更好地再现人类癌症和几何学的模型。伴侣动物会罹患许多相同类型的癌症,携带许多与人类相同的遗传驱动因素,而且与鼠类肿瘤模型相比,狗肿瘤的规模和几何形状更接近于人类。伴侣动物模型可以解决肿瘤学中的关键转化难题,如肿瘤微环境的改变、缺氧、异质性和几何形状。本综述论文将介绍放射性药物靶向技术的背景,回顾放射性药物在伴侣动物肿瘤学中的应用,并从剂量测定、治疗效果和正常组织并发症发生率等方面探讨治疗这些患者的转化价值。
{"title":"The role of companion animal models in radiopharmaceutical development and translation.","authors":"Charles A Maitz, Jeffrey N Bryan","doi":"10.1111/vco.12969","DOIUrl":"10.1111/vco.12969","url":null,"abstract":"<p><p>Advancements in molecular imaging and drug targeting have created a renaissance in the development of radiopharmaceuticals for therapy and theranostics. While some radiopharmaceuticals, such as Na[<sup>131</sup>I]I, have been used clinically for decades, new agents are being approved using small-molecules, peptides, and antibodies for targeting. As these agents are being developed, the need to understand dosimetry and biologic effects of the systemically delivered radiotherapy becomes more important, particularly as highly potent radiopharmaceuticals using targeted alpha therapy become clinically utilized. As the processes being targeted become more complex, and the radiobiology of different particulate radiation becomes more diverse, models that better recapitulate human cancer and geometry are necessary. Companion animals develop many of the same types of cancer, carrying many of the same genetic drivers as those seen in people, and the scale and geometry of tumours in dogs more closely mimics those in humans than murine tumour models. Key translational challenges in oncology, such as alterations in tumour microenvironment, hypoxia, heterogeneity, and geometry are addressed by companion animal models. This review paper will provide background on radiopharmaceutical targeting techniques, review the use of radiopharmaceuticals in companion animal oncology, and explore the translational value of treating these patients in terms of dosimetry, treatment outcomes, and normal tissue complication rates.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140029150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Veterinary and comparative oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1